Advancing Cancer Treatment through Computer-Aided Drug Design – The Babak Lab

The Babak Lab shared a post on LinkedIn:

“Scientific Wednesday.

Advancing Cancer Treatment through Computer-Aided Drug Design (CADD).

The rise in global cancer cases and resistance to traditional therapies highlight the urgent need for new, innovative treatments. Enter Computer-Aided Drug Design (CADD)—a game-changer in accelerating anti-cancer drug discovery!

Key takeaways:

• CADD predicts the efficacy of potential drug compounds, cutting years off the drug discovery timeline.
• Successful CADD discoveries include life-saving drugs like Crizotinib and Axitinib.
• While challenges remain, such as improving simulation accuracy, the future is bright with personalized treatments on the horizon.

CADD is not just about finding new drugs—it’s about finding the right drugs, faster and smarter. Let’s embrace the future of cancer treatment!”

Maria Babak shared this post, adding:

“The ability to predict effective treatments more quickly and efficiently is a real breakthrough!

It gives a clear glimpse into the future of personalized medicine and the technologies that are reshaping the fight against cancer. CADD is revolutionizing the way we approach drug discovery—speeding up research and delivering more precise treatments!

What do you think? How do you see AI-driven drug discovery impacting healthcare? Where else do you think CADD could be applied outside of cancer research?

Let’s discuss how these innovations could change the way we think about healthcare!”

Sources: The Babak Lab/LinkedIn and Maria (Masha) Babak/LinkedIn

More posts featuring The Babak Lab and Maria Babak in OncoDaily.

Dr. Maria (Masha) Babak is the Head of The Babak Lab and an Assistant Professor at the City University of Hong Kong. In November 2020, she joined the City University of Hong Kong as an assistant professor. Dr. Babak received the Graeme Hanson-AsBIC Early Career Award in 2022.

Her research interests are at the intersection of chemistry, biology, and medicine, with a focus on the discovery and preclinical development of anticancer drugs for resistant and aggressive cancers with limited treatment options, such as malignant pleural mesothelioma and brain metastases.